Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Baiyunshan Pharmaceutical Holdings's GHG Emissions Data Preview
In 2023, Baiyunshan Pharmaceutical Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
However, Baiyunshan Pharmaceutical Holdings has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Baiyunshan Pharmaceutical Holdings's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Baiyunshan Pharmaceutical Holdings amounted to 294,796.19 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Baiyunshan Pharmaceutical Holdings increased by 78.64%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Baiyunshan Pharmaceutical Holdings's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Baiyunshan Pharmaceutical Holdings's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Baiyunshan Pharmaceutical Holdings were 171,468.81 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Baiyunshan Pharmaceutical Holdings reduced its Scope 1 emissions over time?
Since 2021, Baiyunshan Pharmaceutical Holdings's Scope 1 emissions have increased by 382.84%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Baiyunshan Pharmaceutical Holdings's Scope 1 emissions increased by 255.08%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Baiyunshan Pharmaceutical Holdings's Scope 2 emissions?
In 2023, Baiyunshan Pharmaceutical Holdings reported Scope 2 greenhouse gas (GHG) emissions of 123,327.38 tCOâ‚‚e without specifying the calculation method.
Has Baiyunshan Pharmaceutical Holdings reduced its Scope 2 emissions over time?
Since 2021, Baiyunshan Pharmaceutical Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 39.04%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Baiyunshan Pharmaceutical Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Baiyunshan Pharmaceutical Holdings 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Baiyunshan Pharmaceutical Holdings use for Scope 2 reporting?
In 2023, Baiyunshan Pharmaceutical Holdings reported its Scope 2 emissions using an unspecified methodology.
Baiyunshan Pharmaceutical Holdings's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Baiyunshan Pharmaceutical Holdings's Value Chain Emissions
In 2023, Baiyunshan Pharmaceutical Holdings reported 17,042.21 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Baiyunshan Pharmaceutical Holdings includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Baiyunshan Pharmaceutical Holdings's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Baiyunshan Pharmaceutical Holdings's Scope 3 emissions?
In 2023, Baiyunshan Pharmaceutical Holdings reported total Scope 3 emissions of 17,042.21 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Insights into Baiyunshan Pharmaceutical Holdings's Total Carbon Footprint
In 2023, Baiyunshan Pharmaceutical Holdings reported a total carbon footprint of 311,838.4 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 88.97% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Baiyunshan Pharmaceutical Holdings's total carbon footprint was Scope 1 emissions, accounting for 54.99% of the company's total carbon footprint, followed by Scope 2 emissions at 39.55%.